Chemical: Drug
dexbrompheniramine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Generic Names
  • D-Brompheniramine
  • Parabromdylamine
  • Parabromodylamine
Trade Names
  • Ilvin
Brand Mixture Names
  • Drixoral Cold & Sinus (Dexbrompheniramine Maleate + Pseudoephedrine Sulfate)
  • Drixoral Day/Night - Srt/Tabs (Dexbrompheniramine Maleate + Pseudoephedrine Sulfate)
  • Drixoral Syrup (Dexbrompheniramine Maleate + Pseudoephedrine Sulfate)
  • Drixtab Tab (Dexbrompheniramine Maleate + Pseudoephedrine Sulfate)

PharmGKB Accession Id

PA164746251

Type(s):

Drug

Description

Dexbrompheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria.

Source: Drug Bank

Indication

For treatment and relief of symptoms of allergies, hay fever, and colds

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Dexbrompheniramine competitively binds to the histamine H 1-receptor. It competes with histamine for the normal H 1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

Source: Drug Bank

Pharmacology

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H 1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexbrompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic (cytochrome P-450 system), some renal.

Source: Drug Bank

Absorption

Antihistamines are well absorbed from the gastrointestinal tract after oral administration.

Source: Drug Bank

Half-Life

25 hours

Source: Drug Bank

Toxicity

Signs of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.

Source: Drug Bank

Chemical Properties

Chemical Formula

C16H19BrN2

Source: Drug Bank

Isomeric SMILES

CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2

Source: Drug Bank

CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=NC=CC=C1

Source: Drug Bank

Canonical SMILES

CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1

Source: Drug Bank

Average Molecular Weight

319.239

Source: Drug Bank

Monoisotopic Molecular Weight

318.073161265

Source: Drug Bank

SMILES

CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1

Source: Drug Bank

InChI String

InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
HRH1 (source: Drug Bank)

Drug Interactions

Interaction Description
donepezil - dexbrompheniramine Possible antagonism of action (source: Drug Bank)
galantamine - dexbrompheniramine Possible antagonism of action (source: Drug Bank)
tacrine - dexbrompheniramine The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dexbrompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank)
trimethobenzamide - dexbrompheniramine Trimethobenzamide and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
triprolidine - dexbrompheniramine Triprolidine and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
triprolidine - dexbrompheniramine Triprolidine and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
trospium - dexbrompheniramine Trospium and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00405
ChEBI:
59269
PubChem Compound:
16960
PubChem Substance:
46505186
669658
Drugs Product Database (DPD):
411892
ChemSpider:
16068
Therapeutic Targets Database:
DAP001068

Clinical Trials

These are trials that mention dexbrompheniramine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.